VelaVigo
VelaVigo is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific antibody-drug conjugates VBC101, VBC103 and VBC108 in advanced solid tumours.
Overview
VelaVigo is a Shanghai-based biotechnology company founded in 2021 that discovers bispecific and multispecific antibodies, antibody-drug conjugates and other biologic modalities for cancer, autoimmune, neurodegenerative and eye diseases. It has first-in-human trials of the bispecific ADCs VBC101, VBC103, VBC106, VBC108 and VBC117 in the United States, Australia and China. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07299747 (phase 1/2, Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors), NCT07136779 (phase 1/2, First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies) and NCT07700160 (phase 1/2, First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.